Synergism between factor XII –4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction

Diana Hernández-Romero; Francisco Marín; Kaeng W. Lee; Vanessa Roldán; Juan Caturla; Javier Corral; Mariano Valdés; Gregory Y. H. Lip; Vicente Vicente; Rocío González-Conejero

doi:10.1160/TH10-01-0022

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 104(03): 650-652
DOI: 10.1160/TH10-01-0022

Letters to the Editor

Schattauer GmbH

Synergism between factor XII –4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction

Authors

Diana Hernández-Romero

¹Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain
Francisco Marín

¹Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain
Kaeng W. Lee

²University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
Vanessa Roldán

³Centro Regional de Hemodonación. Universidad de Murcia, Murcia, Spain
Juan Caturla

⁴Hospital General Universitario de Alicante, Alicante, Spain
Javier Corral

³Centro Regional de Hemodonación. Universidad de Murcia, Murcia, Spain
Mariano Valdés

¹Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain
Gregory Y. H. Lip

²University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
Vicente Vicente

³Centro Regional de Hemodonación. Universidad de Murcia, Murcia, Spain
Rocío González-Conejero

³Centro Regional de Hemodonación. Universidad de Murcia, Murcia, Spain

Abstract

Full Text

References

References
1 Zeerleder S, Schloesser M, Redondo M. et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency -a study on 73 subjects from 14 Swiss families. Thromb Haemost 1999; 82: 1240-1246.
2 Kanaji T, Okamura T, Osaki K. et al. A common genetic polymorphism (46 C to T substitution) in the 5’-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-2014.
3 Millar GJ, Esnouf MP, Burgués AI. et al. Risk of coronary Heart disease and activation of factor XII in middle-aged men. Arterioscl Thromb Vac Biol 1997; 17: 2103-2106.
4 Zito F, Drummond F, Bujac S. et al. Epidemiological and genetic association of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 2000; 102: 2058-2062.
5 Kohler HP, Futres TS, Grant PJ. FXII (46C->T) polymorphism and in vivo generation of FXII activity-gene frequencies and relationship in patients with coronary artery disease. Thromb Haemost 1999; 81: 745-747.
6 Zito F, Lowe GD, Rumley A. et al. WOSCOPS Study. Association of the factor XII 46 C->T polymorphism with risk of coronary heart disease in the WOSCOPS study. Atherosclerosis 2002; 165: 153-158.
7 Santamaría A, Mateo J, Tirado I. et al. Homozygosity of the T allele of the 46 C->T polymorphism in the F12 gene is a risk factor for ischemic stroke in spanish population. Stroke 2004; 35: 1795-1799.
8 Kleinschnitz C, Stoll G, Bendszus M. et al. Targeting coagulation factor XII provides protection form pathological thombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
9 Müller F, Renné T. Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol 2008; 15: 516-521.
10 Armstrong PW, Collen D. Fibrinolityc for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation 2001; 103: 2862-2866.
11 Rallidis LS, Politou M, Komporozos C. et al. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008; 99: 1085-1089.
12 Marín F, González-Conejero R, Lee KW. et al. A pharmacogenetic effect of factor XIII valine 34 Leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2005; 45: 25-29.
13 González-Conejero R, Fernández-Cadenas I, Iniesta JA. et al. for the Proyecto Ictus Research Group. Role of fibrinogen levels and factor XIII V34L polymorphism in thombolytic therapy in stroke patients. Stroke 2006; 37: 2288-2293.
14 Rader DJ, Puré E. Genetic Susceptibility to Atherosclerosis: Insights From Mice. Circ Res 2000; 86: 1013-1015.
15 Bergmann SR, Sobel BE. Noninvasive assessment of the efficacy of coronary thrombolysis. In: Thrombolysis in Cardiovascular Disease. New York, NY: Marcel Dekker; 1989. pp. 141-161.
16 Corral J, González-Conejero R, Iniesta JA. et al. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85: 293-297.
17 Ariëns RAS, Philippou H, Nagaswami C. et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-995.
18 Cannon CP. Importance of TIMI 3 flow. Circulation 2001; 104: 624-627.
19 Gibson CM, Cannon CP, Murphy SA. et al., for the TIMI 10B Investigators. Relationship of TIMI myocardial perfusion grade to mortality following thrombolytic administration. Circulation 2000; 101: 125-130.
20 Syed MA, Borzak S, Asfour A. et al. Single lead ST-segment recovery: a simple, reliable measure of successful fibrinolysis after acute myocardial infarction. Am Heart J 2004; 147: 275-280.
21 Puleo PR, Perryman MB, Bresser MA. et al. Creatine kinase isoform analysis in the detection and assessment of thrombolysis in man. Circulation 1987; 75: 1162-1169.
22 Marín F, González-Conejero R, Capranzano P. et al. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol 2009; 54: 1041-1057.